CTLA4 and neoplasm: The set of major determinants of tumor immunogenicity in CRC we identified included not only immunosuppressive cells and chemokine receptors but also molecules which are currently tested in clinical trials: B7-2 (ligand of CTLA4) and PD-L2 (ligand of PD-1).